Literature DB >> 20056218

The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells.

Xia Luo1, Ping Yin, John S Coon V, You-Hong Cheng, Ronald D Wiehle, Serdar E Bulun.   

Abstract

OBJECTIVE: To evaluate the effects of selective P receptor (PR) modulator CDB4124 on cell proliferation and apoptosis in cultured human uterine leiomyoma smooth muscle (LSM) cells and control myometrial smooth muscle (MSM) cells in matched uteri.
DESIGN: Laboratory research.
SETTING: Academic medical center. PATIENT(S): Premenopausal women (n = 12) undergoing hysterectomy for leiomyoma-related symptoms. INTERVENTION(S): Treatment of primary LSM and MSM cells with CDB4124 (10(-8)-10(-6) M) or vehicle for 24, 48, or 72 hours. MAIN OUTCOME MEASURE(S): Western blot for protein expression of proliferating cell nuclear antigen, cleaved polyadenosine 5'-diphosphate-ribose polymerase, Bcl-2, and Krüppel-like transcription factor 11; 93-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) assay to evaluate viable cell numbers; and real-time polymerase chain reaction (PCR) to quantify messenger RNA (mRNA) levels. RESULT(S): Treatment with CDB4124 significantly decreased levels of the proliferation marker proliferating cell nuclear antigen, the number of viable LSM cells, and the antiapoptotic protein Bcl-2. On the other hand, treatment with CDB4124 increased levels of the apoptosis marker cleaved polyadenosine 5'-diphosphate-ribose polymerase and the tumor suppressor Krüppel-like transcription factor 11 in a dose- and time-dependent manner in LSM cells. In matched MSM cells, however, CDB4124 did not affect cell proliferation or apoptosis. CONCLUSION(S): CDB4124 selectively inhibits proliferation and induces apoptosis in LSM but not in MSM cells. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056218      PMCID: PMC2872031          DOI: 10.1016/j.fertnstert.2009.11.031

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  34 in total

1.  Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells.

Authors:  Qin Xu; Noriyuki Ohara; Wei Chen; Jin Liu; Hiroko Sasaki; Akira Morikawa; Regine Sitruk-Ware; Elof D B Johansson; Takeshi Maruo
Journal:  Hum Reprod       Date:  2006-05-23       Impact factor: 6.918

Review 2.  Antiprogestins: mechanism of action and contraceptive potential.

Authors:  I M Spitz; H B Croxatto; A Robbins
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

Review 3.  Steroid hormones and leiomyomas.

Authors:  Erica E Marsh; Serdar E Bulun
Journal:  Obstet Gynecol Clin North Am       Date:  2006-03       Impact factor: 2.844

4.  Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study.

Authors:  Lauren A Wise; Julie R Palmer; Elizabeth A Stewart; Lynn Rosenberg
Journal:  Obstet Gynecol       Date:  2005-03       Impact factor: 7.661

5.  Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone.

Authors:  H Matsuo; T Maruo; T Samoto
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

Review 6.  Poly (ADP-ribose) polymerase, nitric oxide and cell death.

Authors:  A A Pieper; A Verma; J Zhang; S H Snyder
Journal:  Trends Pharmacol Sci       Date:  1999-04       Impact factor: 14.819

7.  A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.

Authors:  Hiroko Sasaki; Noriyuki Ohara; Qin Xu; Jiayin Wang; Deborah A DeManno; Kristof Chwalisz; Shigeki Yoshida; Takeshi Maruo
Journal:  J Clin Endocrinol Metab       Date:  2006-11-14       Impact factor: 5.958

Review 8.  Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.

Authors:  Kristof Chwalisz; Maria Claudia Perez; Deborah Demanno; Craig Winkel; Gerd Schubert; Walter Elger
Journal:  Endocr Rev       Date:  2005-04-27       Impact factor: 19.871

9.  Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells.

Authors:  Ping Yin; Zhihong Lin; You-Hong Cheng; Erica E Marsh; Hiroki Utsunomiya; Hiroshi Ishikawa; Qing Xue; Scott Reierstad; Joy Innes; Stephen Thung; J Julie Kim; Eugene Xu; Serdar E Bulun
Journal:  J Clin Endocrinol Metab       Date:  2007-09-04       Impact factor: 5.958

10.  Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment.

Authors:  K Englund; A Blanck; I Gustavsson; U Lundkvist; P Sjöblom; A Norgren; B Lindblom
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

View more
  14 in total

1.  Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations.

Authors:  James H Segars; Estella C Parrott; Joan D Nagel; Xiaoxiao Catherine Guo; Xiaohua Gao; Linda S Birnbaum; Vivian W Pinn; Darlene Dixon
Journal:  Hum Reprod Update       Date:  2014-01-08       Impact factor: 15.610

Review 2.  The role of progesterone signaling in the pathogenesis of uterine leiomyoma.

Authors:  J Julie Kim; Elizabeth C Sefton
Journal:  Mol Cell Endocrinol       Date:  2011-06-06       Impact factor: 4.102

3.  Expression of a mitochondrial progesterone receptor (PR-M) in leiomyomata and association with increased mitochondrial membrane potential.

Authors:  Quanling Feng; John R Crochet; Qunsheng Dai; Phyllis C Leppert; Thomas M Price
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

Review 4.  Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.

Authors:  Molly B Moravek; Serdar E Bulun
Journal:  Curr Opin Obstet Gynecol       Date:  2015-08       Impact factor: 1.927

Review 5.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Authors:  Pasquapina Ciarmela; Md Soriful Islam; Fernando M Reis; Peter C Gray; Enrrico Bloise; Felice Petraglia; Wylie Vale; Mario Castellucci
Journal:  Hum Reprod Update       Date:  2011-07-25       Impact factor: 15.610

6.  Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.

Authors:  Nathalie Esber; Clément Cherbonnier; Michèle Resche-Rigon; Abdallah Hamze; Mouad Alami; Jérôme Fagart; Hugues Loosfelt; Marc Lombès; Nathalie Chabbert-Buffet
Journal:  Horm Cancer       Date:  2016-03-03       Impact factor: 3.869

7.  Treatment for Uterine Fibroids: Searching for Effective Drug Therapies.

Authors:  Darlene K Taylor; Phyllis C Leppert
Journal:  Drug Discov Today Ther Strateg       Date:  2012

Review 8.  Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.

Authors:  Molly B Moravek; Ping Yin; Masanori Ono; John S Coon; Matthew T Dyson; Antonia Navarro; Erica E Marsh; Debabrata Chakravarti; J Julie Kim; Jian-Jun Wei; Serdar E Bulun
Journal:  Hum Reprod Update       Date:  2014-09-08       Impact factor: 15.610

9.  A new strategy for selective targeting of progesterone receptor with passive antagonists.

Authors:  Junaid A Khan; Abdellatif Tikad; Michel Fay; Abdallah Hamze; Jérôme Fagart; Nathalie Chabbert-Buffet; Geri Meduri; Larbi Amazit; Jean-Daniel Brion; Mouad Alami; Marc Lombès; Hugues Loosfelt; Marie-Edith Rafestin-Oblin
Journal:  Mol Endocrinol       Date:  2013-04-11

Review 10.  Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.

Authors:  Md Soriful Islam; Sadia Afrin; Sara Isabel Jones; James Segars
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.